The role of a structured intervention on the deprescribing of benzodiazepines in a geriatric population managed in primary care
DOI:
https://doi.org/10.32385/rpmgf.v38i1.13047Keywords:
Deprescription, Benzodiazepines, Hypnotic drugs, Geriatrics, Primary careAbstract
Introduction: Benzodiazepines (BDZ) are widely used to control symptoms in insomnia and anxiety disorders. In the geriatric population, the concerns related to these treatments are higher, and, in addition to the possibility of causing daytime sleepiness, there is also evidence of an association with the increased risk of falls, cognitive decline, and delirium. In this context, it is important to study and evaluate strategies for rational prescribing and deprescribing of BDZ, avoiding prolonged/chronic use whenever it is clinically unnecessary, as well as developing guidelines to manage these therapeutic interventions. Our primary objective was to evaluate the effectiveness of a compound intervention in the rational prescribing/deprescribing of BDZ in geriatric patients managed in primary health care.
Methods: Randomized clinical trial involving two Family Health Units (FHU), attending to test the effectiveness of a compound intervention to improve BDZ prescribing in patients older than 65 years.
Conclusion: After 9 months the chance of not having a prescription for BDZ is, on average, 1,004 times higher (about 0.4%) in the FHU where there was an intervention than in the control, demonstrating that the intervention can be useful. We believe that other studies, methodologically optimized, may be an important contribution to help solve this problem.
Downloads
References
Huerta C, Abbing-Karahagopian VA, Pequena G, Oliva B, Alvarez Y, Gardarsdottir H, et al. Exposure to benzodiazepines (anxiolytics , hypnotics and related drugs) in seven European electronic healthcare databases: a cross- national descriptive study from the PROTECT-EU Project. 2016;25 Suppl 1:56-65.
Baldwin DS, Allgulander C, Bandelow B, Ferre F, Pallanti S. An international survey of reported prescribing practice in the treatment of patients with generalised anxiety disorder. World J Biol Psychiatry. 2012;13(7):510-6.
Baldwin DS, Anderson IM, Nutt DJ, Allgulander C, Bandelow B, den Boer JA, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol. 2014;28(5):403-39.
Anthierens S, Tansens A, Petrovic M, Christiaens T. Qualitative insights into general practitioners views on polypharmacy. BMC Fam Pract. 2010;11:65.
Pek EA, Remfry A, Pendrith C, Fan-Lun C, Bhatia RS, Soong C. High prevalence of inappropriate benzodiazepine and sedative hypnotic prescriptions among hospitalized older adults. J Hosp Med. 2017;12(5):310-6.
Batty GM, Hooper R, Oborne CA, Jackson SH. Investigating intervention strategies to increase the appropriate use of benzodiazepines in elderly medical in-patients. Br J Clin Gov. 2001;6/4):252-8.
Lader M. Benzodiazepines revisited: will we ever learn? Addiction. 2011;106(12):2086-109.
American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2012;60(4):616-31.
Gray SL, LaCroix AZ, Hanlon JT, Penninx BW, Blough DK, Leveille SG, et al. Benzodiazepine use and physical disability in community-dwelling older adults. J Am Geriatr Soc. 2006;54(2):224-30.
Woolcott JC, Richardson KJ, Wiens MO, Patel B, Marin J, Khan KM, et al. Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Arch Intern Med. 2009;169(21):1952-60.
Parsaik AK, Mascarenhas SS, Khosh-Chashm D, Hashmi A, John V, Okusaga O, et al. Mortality associated with anxiolytic and hypnotic drugs: a systematic review and meta-analysis. Aust N Z J Psychiatry. 2016;50(6):520-33.
Palmaro A, Dupouy J, Lapeyre-Mestre M. Benzodiazepines and risk of death: results from two large cohort studies in France and UK. Eur Neuropsychopharmacol. 2015;25(10):1566-77.
Canadian Agency for Drugs and Technology Health. Discontinuation strategies for patients with long-term benzodiazepine use: a review of clinical evidence and guidelines [homepage]. CADTH; 2015. Available from: https://www.ncbi.nlm.nih.gov/books/NBK310990/
Direção-Geral da Saúde. Tratamento sintomático da ansiedade e insónia com benzodiazepinas e fármacos análogos: norma nº 055/2011, de 27/10/2011, atualizada em 21/01/2015. Lisboa: DGS; 2015.
Guaiana G, Barbui C. Discontinuing benzodiazepines: best practices. Epidemiol Psychiatr Sci. 2016;25(3):214-6.
Neutel CI, Skurtveit S, Berg C. What is the point of guidelines? Benzodiazepine and z-hypnotic use by an elderly population. Sleep Med. 2012;13(7):893-7.
Pottie K, Thompson W, Davies S, Grenier J, Sadowski CA, Welch V, et al. Deprescribing benzodiazepine receptor agonists: evidence-based clinical practice guideline. Can Fam Physician. 2018;64(5):339-51.
Donoghue J, Lader M. Usage of benzodiazepines: a review. Int J Psychiatry Clin Pract. 2010;14(2):78-87.
Reeves R. Guideline, education, and peer comparison to reduce prescriptions of benzodiazepines and low-dose quetiapine in prison. J Correct Health Care. 2012;18(1):45-52.
Gould RL, Coulson MC, Patel N, Highton-Williamson E, Howard RJ. Interventions for reducing benzodiazepine use in older people: meta-analysis of randomised controlled trials. Br J Psychiatry. 2014;204(2):98-107.
Serviço Nacional de Saúde. Bilhete de identidade dos indicadores dos cuidados de saúde primários para o ano de 2017 [Internet]. Lisboa: SNS; 2017. Available from: https://www.sns.gov.pt/wp-content/uploads/2017/04/bilhete_identidade_indicadores_contratualizacao_2017.pdf
Ng BJ, Le Couteur DG, Hilmer SN. Deprescribing benzodiazepines in older patients: impact of interventions targeting physicians, pharmacists, and patients. Drugs Aging. 2018;35(6):493-521.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Portuguese Journal of Family Medicine and General Practice
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The authors will assign to the RPMGF the sole right to publish and distribute the content of the manuscript specified in this declaration via physical, electronic, broadcasting or any other medium that may come into existence. They also grant the RPMGF the right to use and exploit this manuscript, in particular by assigning, selling or licensing its content. This permission is permanent and takes effect from the moment the manuscript is submitted, has the maximum duration allowed by applicable Portuguese or international law and is of worldwide scope. The authors further declare that this assignment is made free of charge. If the RPMGF informs the authors that it is not going to publish their manuscript, the exclusive assignment of rights ceases forthwith.
The authors authorise the RPMGF (or any entity it may appoint) to act on their behalf when it believes that copyright may have been infringed.
